Microsomal prostaglandin E synthase-1 and 5-lipoxygenase: potential drug targets in cancer.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 20497297.
- Also identified by DOI 10.1111/j.1365-2796.2010.02246.x.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
There is strong evidence for a role of prostaglandin (PG)E(2) in cancer cell proliferation and tumour development. In PGE(2) biosynthesis, cyclooxygenases (COX-1/2) convert arachidonic acid to PGH(2), which can be isomerized to PGE(2) by PGE synthases, including microsomal PGE synthase-1 (MPGES-1). Data describing genetic deletions of MPGES-1 are reviewed. The results suggest that MPGES-1 is an alternative therapeutic target for cancer cells and tumours that express this enzyme. Several compounds that target COX-2 or MPGES-1 also inhibit 5-lipoxygenase. This may be advantageous for treatment of some forms of cancer.
Medical subject headings
- Antineoplastic Agents
- Enzyme Inhibitors
- Intramolecular Oxidoreductases
- Lipoxygenase Inhibitors
- Neoplasms